Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CiDi Inc.
希迪智駕科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3881)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by CiDi Inc. (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Following the completion of the issuance and listing of the Company's H Shares on the Main Board of the Stock Exchange on December 19, 2025 (the "**Listing**"), the Company shall amend its Articles of Association (the "**Articles of Association**") to reflect the relevant changes in the Company's registered capital, total number of shares, and other matters after the Listing, and complete the filing of such amendments to the Articles of Association.

Pursuant to the resolution passed at the extraordinary general meeting held on September 23, 2024, the Board and its authorized personnel have been authorized to make corresponding adjustments and amendments to the Articles of Association in accordance with the opinions of relevant domestic and overseas regulatory authorities and in light of the Company's actual circumstances.

In view of the above circumstances, the following amendments are made to the Articles of Association:

Article No.	The current Articles of Association	Amended Articles of Association
Article 4	The Company completed the filing with the China Securities Regulatory Commission (hereinafter referred to as the "CSRC") on October 29, 2025 and was approved by The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "Hong Kong Stock Exchange") to initially issue [•] overseas listed foreign shares to the public, and was listed on the Main Board of the Hong Kong Stock Exchange on [•], [•], [•].	The Company completed the filing with the China Securities Regulatory Commission (hereinafter referred to as the "CSRC") on October 29, 2025 and was approved by The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "Hong Kong Stock Exchange") to initially issue ~~[•]~~5,407,980 overseas listed foreign shares to the public, and was listed on the Main Board of the Hong Kong Stock Exchange on ~~[•], [•], [•]~~ December 19, 2025.
Article 7	The registered capital of the Company is RMB[•].	The registered capital of the Company is RMB~~[•]~~43,789,310. The total investment of the Company is RMB76,762,660.
Article 20	The Company was a joint stock limited company transferred from Changsha Intelligent Driving Research Institute Company Limited as a whole, with a total number of shares of [•] shares…….	The Company was a joint stock limited company transferred from Changsha Intelligent Driving Research Institute Company Limited as a whole, with a total number of shares of ~~[•]~~43,789,310 shares…….

Save for the amendments disclosed above, other provisions of the Articles of Association remain unchanged. The amendments to the Articles of Association were prepared in Chinese and the English translation is for reference only. In the event of any discrepancy between the Chinese and English versions, the Chinese version shall prevail.

The full text of the amended Articles of Association is available on the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the website of the Company (www.cidi.ai).

By order of the Board
CiDi Inc.
Dr. Hu Albert Sibo
Executive Director and Chief Executive Officer

Hong Kong, January 13, 2026

As at the date of this announcement, the executive directors of the Company are Dr. Ma Wei and Dr. Hu Albert Sibo; the non-executive directors are Prof. Li Zexiang, Ms. Yang Xi and Dr. Li Zhiyong; and the independent non-executive directors are Dr. Li Xiaoyuan, Prof. Tan Guangrong and Mr. Zhang Jiangang.